MDXH Quote, Financials, Valuation and Earnings

Ion Beam Applications SA has a net margin of -27.65% compared to MDxHealth SA's net margin of --. MDxHealth SA's return on equity of -395.93% beat Ion Beam Applications SA's return on equity of 8.22%.

MDxHealth SA has a consensus price target of $6.0400, signalling upside risk potential of 277.5%. On the other hand Ion Beam Applications SA has an analysts' consensus of -- which suggests that it could fall by --. Given that MDxHealth SA has higher upside potential than Ion Beam Applications SA, analysts believe MDxHealth SA is more attractive than Ion Beam Applications SA.

MDxHealth SA has a beta of -458,274.035, which suggesting that the stock is 45827503.54% less volatile than S&P 500. In comparison Ion Beam Applications SA has a beta of 0.876, suggesting its less volatile than the S&P 500 by 12.377%.

MDxHealth SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ion Beam Applications SA offers a yield of 1.67% to investors and pays a quarterly dividend of $0.18 per share. MDxHealth SA pays -- of its earnings as a dividend. Ion Beam Applications SA pays out -67.19% of its earnings as a dividend.

MDxHealth SA quarterly revenues are $24.7M, which are larger than Ion Beam Applications SA quarterly revenues of --. MDxHealth SA's net income of -$6.8M is higher than Ion Beam Applications SA's net income of --. Notably, MDxHealth SA's price-to-earnings ratio is -- while Ion Beam Applications SA's PE ratio is 46.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MDxHealth SA is 0.67x versus 0.73x for Ion Beam Applications SA. Usually stocks with elevated PS ratios are considered overvalued.

Nyxoah SA has a net margin of -27.65% compared to MDxHealth SA's net margin of -1357.8%. MDxHealth SA's return on equity of -395.93% beat Nyxoah SA's return on equity of -56.62%.

MDxHealth SA has a consensus price target of $6.0400, signalling upside risk potential of 277.5%. On the other hand Nyxoah SA has an analysts' consensus of $15.08 which suggests that it could grow by 152.13%. Given that MDxHealth SA has higher upside potential than Nyxoah SA, analysts believe MDxHealth SA is more attractive than Nyxoah SA.

MDxHealth SA has a beta of -458,274.035, which suggesting that the stock is 45827503.54% less volatile than S&P 500. In comparison Nyxoah SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

MDxHealth SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nyxoah SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MDxHealth SA pays -- of its earnings as a dividend. Nyxoah SA pays out -- of its earnings as a dividend.

MDxHealth SA quarterly revenues are $24.7M, which are larger than Nyxoah SA quarterly revenues of $1.3M. MDxHealth SA's net income of -$6.8M is higher than Nyxoah SA's net income of -$18.3M. Notably, MDxHealth SA's price-to-earnings ratio is -- while Nyxoah SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MDxHealth SA is 0.67x versus 39.97x for Nyxoah SA. Usually stocks with elevated PS ratios are considered overvalued.

Remedent has a net margin of -27.65% compared to MDxHealth SA's net margin of --. MDxHealth SA's return on equity of -395.93% beat Remedent's return on equity of --.

MDxHealth SA has a consensus price target of $6.0400, signalling upside risk potential of 277.5%. On the other hand Remedent has an analysts' consensus of -- which suggests that it could fall by --. Given that MDxHealth SA has higher upside potential than Remedent, analysts believe MDxHealth SA is more attractive than Remedent.

MDxHealth SA has a beta of -458,274.035, which suggesting that the stock is 45827503.54% less volatile than S&P 500. In comparison Remedent has a beta of -0.150, suggesting its less volatile than the S&P 500 by 115.037%.

MDxHealth SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Remedent offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MDxHealth SA pays -- of its earnings as a dividend. Remedent pays out -- of its earnings as a dividend.

MDxHealth SA quarterly revenues are $24.7M, which are larger than Remedent quarterly revenues of --. MDxHealth SA's net income of -$6.8M is higher than Remedent's net income of --. Notably, MDxHealth SA's price-to-earnings ratio is -- while Remedent's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MDxHealth SA is 0.67x versus 0.48x for Remedent. Usually stocks with elevated PS ratios are considered overvalued.

UCB SA has a net margin of -27.65% compared to MDxHealth SA's net margin of --. MDxHealth SA's return on equity of -395.93% beat UCB SA's return on equity of 11.39%.

MDxHealth SA has a consensus price target of $6.0400, signalling upside risk potential of 277.5%. On the other hand UCB SA has an analysts' consensus of -- which suggests that it could fall by --. Given that MDxHealth SA has higher upside potential than UCB SA, analysts believe MDxHealth SA is more attractive than UCB SA.

MDxHealth SA has a beta of -458,274.035, which suggesting that the stock is 45827503.54% less volatile than S&P 500. In comparison UCB SA has a beta of 0.758, suggesting its less volatile than the S&P 500 by 24.243%.

MDxHealth SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UCB SA offers a yield of 0.91% to investors and pays a quarterly dividend of $0.72 per share. MDxHealth SA pays -- of its earnings as a dividend. UCB SA pays out 24.32% of its earnings as a dividend. UCB SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

MDxHealth SA quarterly revenues are $24.7M, which are larger than UCB SA quarterly revenues of --. MDxHealth SA's net income of -$6.8M is higher than UCB SA's net income of --. Notably, MDxHealth SA's price-to-earnings ratio is -- while UCB SA's PE ratio is 27.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MDxHealth SA is 0.67x versus 4.73x for UCB SA. Usually stocks with elevated PS ratios are considered overvalued.